Wire · opportunities
Revolution Medicines Drugged a Target Scientists Called “Undruggable” for Decades. Buy ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 21 November 2026 · Fusion42 review
Revolution Medicines launched Rasonque, a novel oncology drug targeting RAS-addicted cancers, showing strong Phase 3 results and generating $198 million in revenue within five weeks. The drug's success signals a breakthrough against previously 'undruggable' cancer targets, with the company running multiple Phase 3 trials and poised for significant revenue growth.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You now face a new competitor in pancreatic cancer treatment that has drastically improved survival rates. Your moves this week should consider how Rasonque's success could reroute patient demand and redefine treatment standards.
◆ Coverage
1 source · 20 Nov 2026
◆ Related on Wire
◆ Topics